Trial Profile
An Open-label, International, Multicenter, Dose Escalating, Phase I/II Study of HuMax-CD20 in Patients With Relapsed or Refractory Follicular Lymphoma Grade I-II
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 20 Apr 2015 Status changed from completed to withdrawn prior to enrolment as per ClinicalTrials.gov record.
- 26 Nov 2006 New trial record.